Program
Varegacestat Test Formulation A
Also written as “Varegacestat Test Formulation B” and “Varegacestat Test Formulation C”.
Its studies are led by Immunome.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunome | 11 open or running | phase 1since May 20, 2026 | May 20, 2026 | May 2027phase 1 · NCT07610005 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2026First study: phase 1 study in HealthyFirst studyNCT07610005 · 44 planned · United States
Ahead
- May 2027Primary completion: phase 1 study in HealthyNCT07610005
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07610005Healthy · United States | 1 | Recruiting | May 2027 | 44 |
How it is read
Names in the registry
- “Varegacestat Test Formulation A”, 1 entry
- “Varegacestat Test Formulation B”, 1 entry
- “Varegacestat Test Formulation C”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.